Scholarlink

Background <p>In Japan, a two-dose, recombinant herpes zoster vaccine (RZV) has been available since 2020, but vaccination coverage is low because vaccination is voluntary. This study investigated the real-world effectiveness of the RZV for preventing herpes zoster (HZ) by using clinical databases.</p> Methods <p>A retrospective, cohort study was conducted by using databases created at a dermatology clinic in Miyazaki Prefecture, Japan. Vaccinated patients were extracted from the Shingrix Database, and corresponding unvaccinated patients were selected from the Outpatients Database, with individuals matched by sex, age (5-year intervals), and the outpatient visit date (± 3 months from the vaccination date of the vaccinated patient). Cases of HZ as a study outcome were identified by the HZ Database until August 2024. For analysis, a Cox proportional hazard model was used to calculate the hazard ratio (HR) and 95% confidence interval (CI), and vaccine effectiveness was calculated as (1 - HR) × 100 (%).</p> Results <p>Between 2020 and 2023, 612 patients received the RZV, and 612 corresponding unvaccinated patients were extracted from the Outpatients Database. Of them, 2 vaccinated patients (0.3%) and 13 unvaccinated patients (2%) developed HZ from the date of the vaccination/outpatient visit until August 2024 (<i>P</i> &lt; 0.01). The adjusted HR (95% CI) of vaccination for HZ infection was 0.15 (0.03–0.66), giving a vaccine effectiveness of 85%. Effectiveness was the same, regardless of age.</p> Conclusion <p>The RZV provides high effectiveness for preventing HZ in the clinical setting. The necessity or the timing of booster vaccination warrants further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world effectiveness of recombinant herpes Zoster vaccine: a retrospective, cohort study in Japan

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月5日

查看全文
  • Satoko Ohfuji,
  • Nozomu Toyama,
  • Kyoko Kondo,
  • Hisao Muto,
  • Wakaba Fukushima

摘要

Background

In Japan, a two-dose, recombinant herpes zoster vaccine (RZV) has been available since 2020, but vaccination coverage is low because vaccination is voluntary. This study investigated the real-world effectiveness of the RZV for preventing herpes zoster (HZ) by using clinical databases.

Methods

A retrospective, cohort study was conducted by using databases created at a dermatology clinic in Miyazaki Prefecture, Japan. Vaccinated patients were extracted from the Shingrix Database, and corresponding unvaccinated patients were selected from the Outpatients Database, with individuals matched by sex, age (5-year intervals), and the outpatient visit date (± 3 months from the vaccination date of the vaccinated patient). Cases of HZ as a study outcome were identified by the HZ Database until August 2024. For analysis, a Cox proportional hazard model was used to calculate the hazard ratio (HR) and 95% confidence interval (CI), and vaccine effectiveness was calculated as (1 - HR) × 100 (%).

Results

Between 2020 and 2023, 612 patients received the RZV, and 612 corresponding unvaccinated patients were extracted from the Outpatients Database. Of them, 2 vaccinated patients (0.3%) and 13 unvaccinated patients (2%) developed HZ from the date of the vaccination/outpatient visit until August 2024 (P < 0.01). The adjusted HR (95% CI) of vaccination for HZ infection was 0.15 (0.03–0.66), giving a vaccine effectiveness of 85%. Effectiveness was the same, regardless of age.

Conclusion

The RZV provides high effectiveness for preventing HZ in the clinical setting. The necessity or the timing of booster vaccination warrants further investigation.